title: Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.
abstract: BACKGROUND
  Differences in cytokine/chemokine profiles among patients with neuromyelitis optica (NMO), relapsing remitting multiple sclerosis (RRMS), and primary progressive MS (PPMS), and the relationships of these profiles with clinical and neuroimaging features are unclear. A greater understanding of these profiles may help in differential diagnosis.
  
  
  RESULTS
  We measured 27 cytokines/chemokines and growth factors in CSF collected from 20 patients with NMO, 26 with RRMS, nine with PPMS, and 18 with other non-inflammatory neurological diseases (OND) by multiplexed fluorescent bead-based immunoassay. Interleukin (IL)-17A, IL-6, CXCL8 and CXCL10 levels were significantly higher in NMO patients than in OND and RRMS patients at relapse, while granulocyte-colony stimulating factor (G-CSF) and CCL4 levels were significantly higher in NMO patients than in OND patients. In NMO patients, IL-6 and CXCL8 levels were positively correlated with disability and CSF protein concentration while IL-6, CXCL8, G-CSF, granulocyte-macrophage colony-stimulating factor (GM-CSF) and IFN-γ were positively correlated with CSF neutrophil counts at the time of sample collection. In RRMS patients, IL-6 levels were significantly higher than in OND patients at the relapse phase while CSF cell counts were negatively correlated with the levels of CCL2. Correlation coefficients of cytokines/chemokines in the relapse phase were significantly different in three combinations, IL-6 and GM-CSF, G-CSF and GM-CSF, and GM-CSF and IFN-γ, between RRMS and NMO/NMOSD patients. In PPMS patients, CCL4 and CXCL10 levels were significantly higher than in OND patients.
  
  
  CONCLUSIONS
  Our findings suggest distinct cytokine/chemokine alterations in CSF exist among NMO, RRMS and PPMS. In NMO, over-expression of a cluster of Th17- and Th1-related proinflammatory cytokines/chemokines is characteristic, while in PPMS, increased CCL4 and CXCL10 levels may reflect on-going low grade T cell and macrophage/microglia inflammation in the central nervous system. In RRMS, only a mild elevation of proinflammatory cytokines/chemokines was detectable at relapse.
authors: Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors: Takuya
authors: T
authors: Matsushita
authors: Takahisa
authors: T
authors: Tateishi
authors: Noriko
authors: N
authors: Isobe
authors: Tomomi
authors: T
authors: Yonekawa
authors: Ryo
authors: R
authors: Yamasaki
authors: Dai
authors: D
authors: Matsuse
authors: Hiroyuki
authors: H
authors: Murai
authors: Jun-Ichi
authors: J
authors: Kira
mesh_terms: D000328:Adult; D051401:Aquaporin 4 / Q000276:immunology; D018925:Chemokines / Q000134:cerebrospinal fluid*; D016207:Cytokines / Q000134:cerebrospinal fluid*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000134:cerebrospinal fluid; D006801:Humans; D020381:Interleukin-17 / Q000134:cerebrospinal fluid; D015850:Interleukin-6 / Q000134:cerebrospinal fluid; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000134:cerebrospinal fluid*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000134:cerebrospinal fluid*; D009471:Neuromyelitis Optica / Q000134:cerebrospinal fluid*; D012008:Recurrence
chemical_list: C496030:AQP4 protein, human; D051401:Aquaporin 4; D018925:Chemokines; D016207:Cytokines; D020381:Interleukin-17; D015850:Interleukin-6; D016178:Granulocyte-Macrophage Colony-Stimulating Factor
references: Br J Dermatol. 2012 Oct;167(4):717-24
references: 22716185
references: Ann Neurol. 2005 Dec;58(6):840-6
references: 16283615
references: Neurology. 2010 Oct 19;75(16):1423-7
references: 20826711
references: Lancet. 2004 Dec 11-17;364(9451):2106-12
references: 15589308
references: J Neurol Sci. 2007 Jan 15;252(1):57-61
references: 17125797
references: J Exp Med. 2005 Aug 15;202(4):473-7
references: 16087714
references: Mult Scler. 2012 Apr;18(4):398-408
references: 22343184
references: J Immunol. 2003 Dec 1;171(11):6173-7
references: 14634133
references: Clin Exp Immunol. 2000 Nov;122(2):257-63
references: 11091283
references: Eur J Immunol. 1988 Nov;18(11):1797-801
references: 2462501
references: Eur J Immunol. 1990 Sep;20(9):2141-4
references: 2209707
references: Nat Med. 2010 Apr;16(4):406-12
references: 20348925
references: Brain. 2005 May;128(Pt 5):988-1002
references: 15743872
references: Neurology. 2008 Sep 23;71(13):974-81
references: 18809833
references: J Immunol. 2000 Mar 1;164(5):2832-8
references: 10679127
references: Mult Scler. 2009 Jul;15(7):834-47
references: 19465451
references: J Neurol Sci. 2006 Feb 15;241(1-2):25-9
references: 16316662
references: J Neuroimmunol. 2004 Apr;149(1-2):182-6
references: 15020078
references: Neurology. 1999 Sep 22;53(5):1107-14
references: 10496275
references: Ann Neurol. 2009 Nov;66(5):617-29
references: 19938104
references: Nat Immunol. 2005 Nov;6(11):1133-41
references: 16200068
references: Br J Dermatol. 2013 Feb;168(2):412-21
references: 23106107
references: Brain. 2010 Feb;133(Pt 2):349-61
references: 20047900
references: Eur J Neurol. 2004 Jan;11(1):37-42
references: 14692886
references: Neurology. 2009 Nov 17;73(20):1628-37
references: 19917985
references: Mult Scler. 2011 Mar;17(3):335-43
references: 21135023
references: Brain. 2002 Jul;125(Pt 7):1450-61
references: 12076996
references: J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):29-34
references: 23038741
references: Acta Neuropathol. 2012 May;123(5):627-38
references: 22327362
references: Brain. 2007 May;130(Pt 5):1194-205
references: 17282996
references: Eur J Neurol. 2001 Nov;8(6):665-72
references: 11784351
references: J Neuroimmunol. 1998 May 1;85(1):33-43
references: 9626995
references: Neurology. 1983 Nov;33(11):1444-52
references: 6685237
references: J Exp Med. 2003 Dec 15;198(12):1951-7
references: 14662908
references: J Clin Invest. 1999 May;103(9):1345-52
references: 10225978
references: Brain Pathol. 2011 Sep;21(5):516-32
references: 21241398
references: Mult Scler. 2010 Dec;16(12):1443-52
references: 20739337
references: Arch Neurol. 2008 Jan;65(1):78-83
references: 18195142
references: Neurology. 2006 May 23;66(10):1485-9
references: 16717206
references: J Immunol. 2010 Nov 15;185(10):5693-703
references: 20926794
references: Brain. 2010 Sep;133(9):2578-91
references: 20688809
references: Br J Dermatol. 2013 Feb;168(2):402-11
references: 23362969
references: J Neuroimmunol. 2008 Mar;195(1-2):121-34
references: 18234356
references: Cytokine Growth Factor Rev. 2002 Dec;13(6):455-81
references: 12401480
references: Ann Neurol. 2009 Nov;66(5):630-43
references: 19937948
references: Nat Immunol. 2005 Nov;6(11):1123-32
references: 16200070